Dimensional Fund Advisors LP Has $104.76 Million Position in Henry Schein, Inc. (NASDAQ:HSIC)

Dimensional Fund Advisors LP boosted its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 10.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,634,384 shares of the company’s stock after purchasing an additional 149,517 shares during the period. Dimensional Fund Advisors LP owned about 1.28% of Henry Schein worth $104,764,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Swedbank AB bought a new position in Henry Schein during the 1st quarter worth $215,998,000. Thompson Siegel & Walmsley LLC acquired a new position in Henry Schein during the 2nd quarter valued at about $46,683,000. Nuance Investments LLC lifted its position in shares of Henry Schein by 28.5% during the 1st quarter. Nuance Investments LLC now owns 1,755,190 shares of the company’s stock worth $132,552,000 after buying an additional 388,843 shares in the last quarter. Fiduciary Management Inc. WI lifted its position in shares of Henry Schein by 17.1% during the 4th quarter. Fiduciary Management Inc. WI now owns 2,284,337 shares of the company’s stock worth $172,947,000 after buying an additional 333,855 shares in the last quarter. Finally, KBC Group NV lifted its position in shares of Henry Schein by 163.5% during the 4th quarter. KBC Group NV now owns 521,964 shares of the company’s stock worth $39,518,000 after buying an additional 323,901 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Henry Schein

In related news, SVP Lorelei Mcglynn sold 21,035 shares of the stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $69.30, for a total value of $1,457,725.50. Following the sale, the senior vice president now directly owns 71,833 shares of the company’s stock, valued at approximately $4,978,026.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.14% of the company’s stock.

Henry Schein Price Performance

Shares of HSIC opened at $71.63 on Tuesday. The firm has a market cap of $9.17 billion, a PE ratio of 24.20, a P/E/G ratio of 1.88 and a beta of 0.86. The company has a current ratio of 1.55, a quick ratio of 0.90 and a debt-to-equity ratio of 0.46. The firm has a fifty day simple moving average of $70.00 and a two-hundred day simple moving average of $70.29. Henry Schein, Inc. has a 1-year low of $60.01 and a 1-year high of $82.63.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $1.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.22 by $0.01. Henry Schein had a net margin of 2.82% and a return on equity of 13.19%. The firm had revenue of $3.10 billion during the quarter, compared to the consensus estimate of $3.27 billion. During the same quarter in the previous year, the firm posted $1.31 EPS. The company’s revenue for the quarter was up .0% compared to the same quarter last year. On average, equities analysts anticipate that Henry Schein, Inc. will post 4.75 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on HSIC. Piper Sandler reaffirmed an “overweight” rating and issued a $86.00 price target on shares of Henry Schein in a report on Friday, June 21st. Robert W. Baird lowered their price target on shares of Henry Schein from $92.00 to $82.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. Baird R W raised shares of Henry Schein from a “hold” rating to a “strong-buy” rating in a report on Monday, July 22nd. Evercore ISI lowered their price target on shares of Henry Schein from $72.00 to $70.00 and set an “in-line” rating on the stock in a report on Wednesday, August 7th. Finally, UBS Group lowered their price target on shares of Henry Schein from $75.00 to $72.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, six have given a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $77.10.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.